HeyJaredStock Chart Alerts
Written by a Wall Street veteran with over 120,000 subscribers, this newsletter provides in-depth analysis and commentary on the latest market trends and stock picks. This is a Substack Bestselling publication.
- Indexed issues, last 90 days
- 15
- Latest publication
- Sep 30, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 14, 2026
Latest issues
$DNA +85% Since Our Alert. This Is Why You Read Stock Chart Alerts. (opens the original)
Read excerpt
Hi Students, Traders and VIP Program members,Chartist here, and I’m going to let the numbers talk first.We alerted Ginkgo Bioworks (NYSE: DNA) at $6.56. Today it hit $12.26 after a 16% single-day surge. That’s a gain of 85% since our alert. In a matter of weeks.<sourc
$DNA Rips 12% Today. +47% Since We Alerted It. (opens the original)
Read excerpt
Hey traders and VIP members,Sir Chartist here… and what a morning.Ginkgo Bioworks (NYSE: DNA) is up 12% today and just printed $9.63. When we put this name in front of you, it was $6.56 and Wall Street had it rated Sell. Nobody was talking about it. Now it’s up 47% from our alert, and every financial outlet is suddenly discovering the “autonomous lab” story we laid out for you weeks ago.That’s not luck. That’s the work.<a class="image-link image2 is-viewable-img" href="https://substackcdn.com/im
CRDL: Digging Deeper — Why the MAVERIC Expansion Could Be the Smartest Move Cardiol Has Made (opens the original)
Read excerpt
CRDL: Digging Deeper — Why the MAVERIC Expansion Could Be the Smartest Move Cardiol Has MadeNASDAQ: CRDL | Cardiol Therapeutics Inc. | Sponsored Follow-Up Alert<img alt="" class="sizing-normal" height="146
Wall Street Doubles Down: H.C. Wainwright Reiterates Buy on CRDL, Holds $9 Target (opens the original)
Read excerpt
Wall Street Doubles Down: H.C. Wainwright Reiterates Buy on CRDL, Holds $9 TargetNASDAQ: CRDL | Cardiol Therapeutics Inc. | Sponsored Flash Alert — September 23, 2026Just InH.C. Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on Cardiol Therapeutics (NASDAQ: CRDL), maintaining a $9 price target (Currently at 1.86)Subscribe now<div c
CRDL Hits Phase III Enrollment Target Early — and Expands the Pivotal Trial (opens the original)
Read excerpt
CRDL Hits Phase III Enrollment Target Early — and Expands the Pivotal TrialNASDAQ: CRDL | Cardiol Therapeutics Inc. | September 23, 2026| Sponsored ContentThe News (Released Today)Subscribe nowThis morning, Cardiol Therapeutics (NASDAQ: CRDL) announced that its pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis has achieved its or
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.